Angela Falola

Mrs. Angela Falola


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
AFAngela Falola
Angela Falola
ADAlicia Demirjian
Alicia Demirjian
Wendy ThompsonWendy Thompson
Wendy Thompson
CBColin S Brown
Colin S Brown
SGSarah Gerver
Sarah Gerver
SBSabine Bou-Antoun
Sabine Bou-Antoun
Reducing inappropriate antibiotic prescribing tempers the growing threat of antimicrobial resistance. We aimed to quantify the associated impact of COVID-19-related national restrictions in England on dental antibiotic dispensing and describe changes in appointments and modes of delivery of care. Interrupted time series analyses were completed using NHS Business Service Authority (NHSBSA) ePACT2 data to measure the associated change in antibiotic dispensing in England following COVID-19-related restrictions (which began March 2020). For face-to-face dental consultations, NHS dental treatment plan (FP17) data were used. For remote consultations during the COVID-19 period, NHSBSA Compass system remote management data were used. Between January 2016 and February 2020, there was a decreasing trend in antibiotic dispensing (−0.02 per 1000 population per month, P < 0.05). In contrast, there was an increase of 0.98 per 1000 population (P < 0.05) in March. The peak in antibiotic use occurred between June 2020 and July 2020, once the restrictions were eased. At the end of the study period (July 2021), the elevated prescribing trend had not returned to pre-pandemic counterfactual levels, although exhibiting a declining trend. A stable trend in dental treatment plans was seen pre-COVID-19, with a sharp decline coinciding with the restrictions. Dental treatment plans had not yet returned to the higher pre-pandemic levels. Dental antibiotic prescribing significantly increased with the national COVID-19 restrictions when service delivery was altered with the closure of dental practices and introduction of remote consultations. Teledentistry was likely associated with inappropriate antibiotic prescribing. Continued antimicrobial stewardship and prudent use of antibiotics in dentistry is important.

18 January 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
SBSabine Bou-Antoun
Sabine Bou-Antoun
AFAngela Falola
Angela Falola
HFHolly Fountain
Holly Fountain
HSHanna Squire
Hanna Squire
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
The UK’s 5-year National Action Plan for Antimicrobial Resistance has an ambition to reduce total antimicrobial consumption, a key driver of antimicrobial resistance, in humans by 15% by 2024, highlighting the need for active surveillance to inform on progression. The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report, Chapter 3, commentates on key national antimicrobial consumption trends, across primary and secondary care in England, between 2017 to 2021. These findings were presented at the ESPAUR Report webinar on 23 November 2022.

15 May 2024 in COVID
Verified
Journal Article
Open access
PDF file
AFAngela Falola
Angela Falola
HSHanna Squire
Hanna Squire
SBSabine Bou-Antoun
Sabine Bou-Antoun
ALAlessandra Lochen
Alessandra Lochen
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®)—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®)—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics’ use in England between 2022 and 2023.

20 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AFAngela Falola
Angela Falola
HSHanna Squire
Hanna Squire
SBSabine Bou-Antoun
Sabine Bou-Antoun
ALAlessandra Lochen
Alessandra Lochen
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor usage of COVID-19 therapeutics in hospital and community settings and inform stewardship. Three antiviral therapies: nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®); and two neutralising monoclonal antibody therapies (nMAbs): sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®); were in use in England between July 2020 to April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report 2022 to 2023 also discusses the epidemiological surveillance of these five directly-acting antiviral COVID-19 therapeutics use in England between 2022 to 2023.